New PR shop to offer nimble alternatives

Hoping to address PR needs in light of shrinking budgets, Shannon Troughton has launched VoxPop Public Relations, in Indianapolis.

Troughton, who was most recently VP of corporate communications at US-based health insurer WellPoint, said the time was right for a smaller, more agile offering in the healthcare and technology PR sector.

“Companies can't afford to pay $400,000 retainers monthly or even annually to get the same experience that I have, with no overhead,” said Troughton, who has served as director of communications for GE Healthcare, and VP of corporate and public affairs at Fleishman-Hillard. 

VoxPop has already secured clients such as dLife, the online diabetes community, MDdatacor, a clinical patient data provider, and Alaven Healthcare, an Atlanta-based specialty company focused on women's health, gastroenterology and anemia.

VoxPop hopes to attract healthcare and pharma clients that have a unique technology to offer, specifically, notes Troughton, clients that “know how to talk to investors and shareholders, but need help with publicity,” she says. She began her career as a communications staffer for the late Missouri governor, Mel Carnahan. 
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.